Donanemab, another controversial drug which costs about 60-80,000 per year, shows a 0.7 point difference at 76 weeks, which is roughly 33% slower than placebo
Like semaglutide, the starting dose of 2.5 mg is not the therapeutic dose
When normal eating resumes even gradually stored calories accumulate faster than before the program
For patients using peptide therapy for weight management, metabolic support, recovery, body composition, or healthy aging goals, predictable handling helps support predictable follow-up
On shot day, stay soft and small
The first agent in this class, exenatide, was approved by the FDA in 2005